Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I
The calcineurin inhibitors ciclosporin (cyclosporine) and tacrolimus are immunosuppressant
drugs used for the prevention of organ rejection following transplantation. Both agents are …
drugs used for the prevention of organ rejection following transplantation. Both agents are …
Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics
K Iwasaki - Drug metabolism and pharmacokinetics, 2007 - Elsevier
Tacrolimus (FK506), an immunosuppressive drug, is co-medicated with multiple drugs under
clinical conditions. Tacrolimus is highly lipophilic and is excreted from the body after …
clinical conditions. Tacrolimus is highly lipophilic and is excreted from the body after …
Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first‐and third‐generation Japanese populations: comparison with Korean …
SP Myrand, K Sekiguchi, MZ Man, X Lin… - Clinical …, 2008 - Wiley Online Library
Application of foreign clinical data across geographic regions can accelerate drug
development. Drug disposition can be variable, and identification of factors influencing …
development. Drug disposition can be variable, and identification of factors influencing …
CYP3A5 and CYP3A4 but not MDR1 Single‐nucleotide Polymorphisms Determine Long‐term Tacrolimus Disposition and Drug‐related Nephrotoxicity in Renal …
DRJ Kuypers, H De Jonge, M Naesens… - Clinical …, 2007 - Wiley Online Library
The impact of CYP3A and MDR1 gene single‐nucleotide polymorphisms on long‐term
tacrolimus disposition and drug‐related toxicity has not been assessed. A study was …
tacrolimus disposition and drug‐related toxicity has not been assessed. A study was …
Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium
PA Jacobson, WS Oetting, AM Brearley, R Leduc… - …, 2011 - journals.lww.com
Background. The CYP4503A5* 1 genotype is associated with lower tacrolimus
concentrations. Although its effect is important, it incompletely explains the variability in …
concentrations. Although its effect is important, it incompletely explains the variability in …
Intestinal efflux transporters and drug absorption
T Murakami, M Takano - Expert opinion on drug metabolism & …, 2008 - Taylor & Francis
Background: The intestinal epithelial membrane expresses ATP-binding cassette (ABC)
transporters such as P-glycoprotein (P-gp), multi-drug resistance-associated proteins …
transporters such as P-glycoprotein (P-gp), multi-drug resistance-associated proteins …
Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients
W Zhao, V Elie, G Roussey, K Brochard… - Clinical …, 2009 - Wiley Online Library
The aim of this study was to develop a population pharmacokinetic model of tacrolimus in
pediatric kidney transplant patients, identify factors that explain variability, and determine …
pediatric kidney transplant patients, identify factors that explain variability, and determine …
The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation
P Stratta, M Quaglia, T Cena, R Antoniotti… - European journal of …, 2012 - Springer
Purpose The aim of this study was to evaluate the effect of different clinical covariates on
tacrolimus dose requirements in adult kidney transplant patients with a specific focus on …
tacrolimus dose requirements in adult kidney transplant patients with a specific focus on …
The combination of CYP3A4* 22 and CYP3A5* 3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation
N Lloberas, L Elens, I Llaudó, A Padullés… - Pharmacogenetics …, 2017 - journals.lww.com
Results EM had an 88% lower dose-adjusted C 0 compared with IM. PM had a 26% higher
dose-adjusted C 0 compared with IM. The percentage of patients with supratherapeutic Tac …
dose-adjusted C 0 compared with IM. The percentage of patients with supratherapeutic Tac …
Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients
M Fukudo, I Yano, A Yoshimura… - Pharmacogenetics …, 2008 - journals.lww.com
Objective The potential influence of the multidrug resistance 1 (MDR1) gene and the
cytochrome P450 (CYP) genes, CYP3A4 and CYP3A5, on the oral clearance (CL/F) of …
cytochrome P450 (CYP) genes, CYP3A4 and CYP3A5, on the oral clearance (CL/F) of …